Development of Sr-incorporated biphasic calcium phosphate bone cement

Current bone cements face limitations in degradation rates and mechanical performance. Traditional biphasic calcium phosphate ceramics have been widely studied for their potential in bone regeneration. However, the specific effects of strontium incorporation on these materials remain unclear. Prior research has shown that calcium phosphate cements can be tailored for controlled degradation, but the role of strontium in this context is not fully understood. This gap motivated the investigation of strontium-doped composites. No prior work had resolved how strontium affects both phase composition and degradation behavior. The need for improved biocompatible materials with tunable properties remains unmet. This paper's contribution lies in its first-time exploration of strontium-doped biphasic calcium phosphate bone cement. The study introduces a novel approach to enhancing degradation rates while maintaining structural integrity.

The aim of this study was to develop and characterize strontium-doped biphasic calcium phosphate bone cement (Sr-BCPC) for potential use in orthopedic applications. The researchers sought to determine how varying strontium content affects the material's properties. A key problem addressed was the need for bone cements with tunable degradation rates. The motivation stemmed from the desire to improve the performance of traditional calcium phosphate cements. The study focused on evaluating phase composition, mechanical strength, and cytotoxicity. The researchers also aimed to assess in vitro degradation behavior. This work sought to bridge the gap between material design and biological performance. The ultimate goal was to identify a formulation that balances degradation rate and mechanical stability.

The study used Sr-doped β-tricalcium phosphate (Sr-β-TCP) and tetracalcium phosphate (TTCP) as cement powder components. Diluted phosphoric acid served as the cement liquid. The researchers prepared Sr-BCPC composites with varying strontium concentrations. Phase composition was analyzed using standard analytical techniques. Mechanical properties were tested via compression strength measurements. The setting time was evaluated under controlled conditions. In vitro degradation was simulated using a body fluid solution. Cytotoxicity was assessed using standard cell culture methods. The study also examined microstructure evolution and hydration dynamics.

The final cement product contained entangled Sr-HAP nano-needles and cobblestone-like Sr-β-TCP particles. After 24 hours in simulated body fluid, Sr-HAP ranged from 60 to 70 weight percent. Sr-β-TCP accounted for 30 to 40 weight percent. Strontium content significantly influenced phase composition and mechanical properties. The compressive strength varied with strontium concentration. Setting time was affected by the presence of strontium. The in vitro degradation rate increased with higher Sr-β-TCP content. Cytotoxicity tests showed that the material remained biocompatible within tested ranges.

The study demonstrated that strontium incorporation significantly affects the properties of biphasic calcium phosphate bone cement. The biphasic design improved degradation rates without compromising structural integrity. The researchers propose that this approach offers a viable strategy for tailoring bone cement performance. The findings suggest that Sr-BCPC can be optimized for specific clinical applications. The observed increase in degradation rate with Sr-β-TCP content supports this conclusion. The material's biocompatibility was confirmed through cytotoxicity tests. The study highlights the importance of phase composition in determining material behavior. The authors suggest that further work could explore long-term in vivo performance.